



5-3-05

CASE PA/4-30602B

Ifw
ab

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
EV483664233US	May 2, 2005
Express Mail Label Number	Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

DE BRUIJN ET AL.

Examiner: Delacroix Muirhei, Cybille

APPLICATION NO: 10/620,178

FILED: JULY 15, 2003

FOR: NEW ORAL FORMULATION

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed July 15, 2003. Since it is being filed in accordance with 37 C.F.R. §1.97(c), a letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.


The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7960

Date:

April 29, 2005

Respectfully submitted,


Edward J. Wilusz, Jr.
Attorney for Applicants
Reg. No. 52,370

05/04/2005 JBALINAN 00000058 190134 10620178

01 FC:1806

180.00 DA



CASE PA/4-30602B

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
<i>EV48366923US</i>	<i>May 2, 2005</i>
Express Mail Label Number	Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

DE BRUIJN ET AL.

Examiner: Delacroix Muirhei, Cybille

APPLICATION NO: 10/620,178

FILED: JULY 15, 2003

FOR: NEW ORAL FORMULATION

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).


An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7960


Date:

April 29, 2005


Edward J. Wilusz, Jr.
Attorney for Applicants
Reg. No. 52,370

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
PA/4-30602B
APPLICATION NO.
10/620,178
APPLICANT
DE BRUIJN ET AL.
FILING DATE
JULY 15, 2003Group
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 97/22340	12/19/96	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	JP 9-194374A (English Translation)	11/8/96	Japan			<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	
	AS	
	AT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.